This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Santini, D. Articles by Tonini, G. Search for Related Content PubMed PubMed Citation Articles by Santini, D. Articles by Tonini, G.

Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients

Authors' Affiliations: ¹ Medical Oncology and ² Department of Laboratory Medicine, University Campus Bio-Medico, Rome, Italy, and ³ Experimental Pharmacology Unit, National Cancer Institute of Naples "Fondazione G. Pascale," Naples, Italy

Requests for reprints: Daniele Santini, Medical Oncology, University Campus Bio-Medico, 00155 Rome, Italy. Phone: 39-6-2254-1737; Fax: 39-6-2254-1520; E-mail: d.santini{at}uicampus.it.

Purpose: On the basis of stimulating data on animals reporting that weekly regimens of zoledronic acid (ZA) were effective in reducing skeletal tumor burden, we designed a study on humans to investigate the potential antiangiogenic role of a weekly low-dose therapy with ZA in patients with malignancies.

Experimental Design: Twenty-six consecutive patients with advanced solid cancer and bone metastases received 1 mg of ZA every week for four times (days 1, 7, 14, and 21) followed by 4 mg of ZA with a standard 28-day schedule repeated thrice (days 28, 56, and 84). Patients were prospectively evaluated for circulating levels of vascular endothelial growth factor (VEGF) just before the beginning of drug infusion (0) and again at 7, 14, 21, 28, 56, and 84 days after the first ZA infusion.

Results: The median VEGF basal value showed an early statistically significant (P = 0.038) decrease 7 days after the first 1-mg infusion of ZA. This effect on VEGF-circulating levels persisted also after the following 1-mg infusions at 14 (P = 0.002), 21 (P = 0.001), and 28 days (P = 0.008). Interestingly, the decrease of VEGF-circulating levels persisted also at each programmed time point during the second phase of the study (ZA 4 mg every 4 weeks). No significant differences were recorded in platelet levels, WBC count, or hemoglobin concentration before and after each ZA infusion.

Conclusions: In the present study, we report that a repeated low-dose therapy with ZA is able to induce an early significant and long-lasting decrease of VEGF levels in cancer patients.

This article has been cited by other articles:

				P. Clezardin Insights into the Antitumor Effects of Bisphosphonates from Preclinical Models and Potential Clinical Implications IBMS BoneKEy, June 1, 2009; 6(6): 210 - 217. [Abstract] [Full Text] [PDF]

				E Amir, M Trinkaus, C E Simmons, G Dranitsaris, and M J Clemons Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer J. Clin. Pathol., May 1, 2009; 62(5): 474 - 476. [Abstract] [Full Text] [PDF]

				M. Gnant, B. Mlineritsch, W. Schippinger, G. Luschin-Ebengreuth, S. Postlberger, C. Menzel, R. Jakesz, M. Seifert, M. Hubalek, V. Bjelic-Radisic, et al. Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer N. Engl. J. Med., February 12, 2009; 360(7): 679 - 691. [Abstract] [Full Text] [PDF]

				M. P. Brizzi, C. M. Sculli, F. Ragni, F. Porpiglia, M. Tampellini, G. Gorzegno, A. M. Priola, L. Dogliotti, and A. Berruti Activity and safety of a prolonged daily schedule of zoledronic acid in a patient with bone metastases from urothelial carcinoma Ann. Onc., February 1, 2009; 20(2): 389 - 390. [Full Text] [PDF]

				G. Ferretti, A. Fabi, P. Carlini, P. Papaldo, A. Felici, S. Tomao, and F. Cognetti Zoledronic Acid and Angiogenesis Clin. Cancer Res., November 15, 2007; 13(22): 6850 - 6850. [Full Text] [PDF]

				D. Santini, B. Vincenzi, and G. Tonini Zoledronic Acid and Angiogenesis Clin. Cancer Res., November 15, 2007; 13(22): 6850 - 6851. [Full Text] [PDF]

				D.B. Kimmel Mechanism of Action, Pharmacokinetic and Pharmacodynamic Profile, and Clinical Applications of Nitrogen-containing Bisphosphonates Journal of Dental Research, November 1, 2007; 86(11): 1022 - 1033. [Abstract] [Full Text] [PDF]